Vorapaxar sulfate is primarily used in the prevention of thrombotic cardiovascular events. It is specifically prescribed to reduce the risk of heart attack, stroke, cardiovascular death, and other complications in patients with a history of myocardial infarction or peripheral arterial disease. The drug works by inhibiting the protease-activated receptor-1 (PAR-1), which plays a key role in platelet activation and thrombus formation. This targeted mechanism helps prevent excessive blood clotting without significantly increasing the risk of bleeding, making it a valuable option for patients who require long-term antiplatelet therapy. It is often used in combination with other antiplatelet agents like aspirin or clopidogrel to enhance its efficacy in managing cardiovascular risks. However, it is contraindicated in patients with a history of stroke, transient ischemic attack, or intracranial hemorrhage due to the increased risk of bleeding.